Immunomodulatory effect of mesenchymal stem cells‐derived extracellular vesicles to modulate the regulatory T cells and Th1/Th2 imbalance in peripheral blood mononuclear cells of patients with allergic rhinitis DOI
Zhao Wang, Khawar Ali Shahzad, Xuran Li

et al.

Scandinavian Journal of Immunology, Journal Year: 2024, Volume and Issue: 100(6)

Published: Oct. 29, 2024

Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have shown promising immunomodulatory capabilities for a variety of clinical conditions. However, the potential regulatory mechanisms MSC-EVs in allergic rhinitis (AR) remain unexplored. The present study was designed to investigate effect patients with AR. Peripheral blood mononuclear cells (PBMCs) were isolated from AR patients. number peripheral CD4

Language: Английский

Administration Strategy-Dependent Mechanisms and Effects of Human Adipose Tissue Stem Cell Extracellular Vesicles in Mouse Allergic Rhinitis Treatment DOI Creative Commons
Wenhan Yang, Zhiyu Pan, Jiacheng Zhang

et al.

Cell Transplantation, Journal Year: 2025, Volume and Issue: 34

Published: April 1, 2025

We previously found that intravenous injection of extracellular vesicles (EVs) from human adipose tissue–derived stem cells (hADSC) could ameliorate allergic rhinitis (AR) in mice through immunomodulatory effects. In clinical trials, nasal delivery has been an attractive treatment for AR. sought to determine whether there are differences the therapeutic effects between caudal and their combination. treated AR with ADSC-EVs via vein, cavity, or both. After treatment, were re-sensitized indices behavior, mucosa morphology, cytokine secretion under different modes administration calculated. The resultes show tail nasal, combined effectively relieve inflammatory infiltration mice, reduce IgE, IL-4, other factors, alleviate Th1/Th2 imbalance. Injection delivery, as well combination, alleviated symptoms mice. Nasal a better effect when response is mild. It be speculated have excellent properties AR, can selected stages therapy.

Language: Английский

Citations

0
The Immunomodulatory mechanism and research progress of mesenchymal stem cells in the treatment of allergic rhinitis DOI Creative Commons

Yu-Meng Ye,

Yuxin Zhao, Li‐xin Xiang

et al.

Stem Cell Research & Therapy, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 18, 2025

Allergic rhinitis (AR) affects 10-40% of the global population, yet current therapies (drugs, immunotherapy) face limitations in efficacy and safety. Mesenchymal stem cells (MSCs) have emerged as a promising alternative due to their immunomodulatory properties. Preclinical studies demonstrate that MSCs from adipose, bone marrow, umbilical cord, tonsils reduce AR symptoms (sneezing, nasal inflammation) serum IgE (Immunoglobulin E) levels by restoring Th1/Th2 immune equilibrium enhancing Treg (Regulatory T cells) activity. MSC-derived exosomes hydrogel-encapsulated formulations further improve targeting However, clinical translation is hindered heterogeneous protocols unresolved long-term risks (e.g., tumorigenicity). MSC-based offer potential for durable remission addressing dysregulation at its root. Future efforts must prioritize standardized production, phase I safety trials, combination strategies + hydrogels) accelerate adoption.

Language: Английский

Citations

0
Functions and Clinical Applications of Extracellular Vesicles in TH2 Cell-Mediated Airway Inflammatory Diseases: A Review DOI Open Access

Jaehwan Cheon,

Byoungjae Kim, Juhyun Lee

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9455 - 9455

Published: Aug. 30, 2024

Type 2 airway inflammation (T2AI), driven by type innate lymphoid and CD4

Language: Английский

Citations

2
Mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis: role and therapeutic directions DOI Creative Commons
Xuan Wang,

Jiaying Guo,

Qinggang Dai

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: Oct. 17, 2024

Systemic sclerosis (SSc) is a complex autoimmune disease with clinical symptoms of vascular damage, immune disorders, and fibrosis, presenting significant treatment challenges limited therapeutic options. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have been demonstrated in numerous studies as more effective than MSCs treating diseases. Recent demonstrate that MSC-EVs can significantly ameliorate the SSc mitigate pathological changes such injury, dysregulation, fibrosis. These findings underscore promising potential SSc. promote angiogenesis, modulate dysfunction, combat This article summarizes applications possible mechanisms for SSc, thereby offering novel direction

Language: Английский

Citations

1
Immunomodulatory effect of mesenchymal stem cells‐derived extracellular vesicles to modulate the regulatory T cells and Th1/Th2 imbalance in peripheral blood mononuclear cells of patients with allergic rhinitis DOI
Zhao Wang, Khawar Ali Shahzad, Xuran Li

et al.

Scandinavian Journal of Immunology, Journal Year: 2024, Volume and Issue: 100(6)

Published: Oct. 29, 2024

Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have shown promising immunomodulatory capabilities for a variety of clinical conditions. However, the potential regulatory mechanisms MSC-EVs in allergic rhinitis (AR) remain unexplored. The present study was designed to investigate effect patients with AR. Peripheral blood mononuclear cells (PBMCs) were isolated from AR patients. number peripheral CD4

Language: Английский

Citations

0